Contrast-induced nephropathy: Update with special emphasis on patients with diabetes

Current Diabetes Reports

Volumn 7, Issue 6, 2007, Pages 454-458

  Solomon, Richard ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DOPAMINE; FENOLDOPAM; GADOLINIUM CHELATE; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOPAMIDOL; PROSTAGLANDIN E2; THEOPHYLLINE; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FLUID THERAPY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEAT SENSATION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HYPOTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PRIMARY PREVENTION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SIDE EFFECT;

CONTRAST MEDIA; DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE; RENAL DIALYSIS;

EID: 37349066751     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0077-4     Document Type: Review

References (25)

1. Persson B, Hansell P, Liss P: Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005, 68:14-22.
2. Economides PA, Caselli A, Zuo CS, et al.: Kidney oxygenation during water diuresis and endothelial function in patients with type 2 diabetes and subjects at risk to develop diabetes. Metabolism 2004, 53:222-227.
3. McCullough P, Sandberg KA: Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003, 4(suppl 5):S3-S9.
4. Toprak O, Cirit M, Yesit M, et al.: Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant 2006, 22:819-826.
5. McCullough PA, Adam A, Becker CR, et al.: Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006, 98(suppl):5K-13K.
6. Mehran R, Aymong ED, Nikolsky E, et al.: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004, 44:1393-1399.
7. Mueller C: Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int 2006, 69:S16-S19.
8. Tepel M, Van Der Giet M, Schwarzfeld C, et al.: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
9. Diaz-Sandoval L, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002, 89:356-358.
10. Zagler A, Azadpour M, Mercado C, Hennekens CH: N-acetylcysteine and contrast-induced nephropathy: A meta-analysis of 13 randomized trials. Am Heart J 2006, 151:140-145.
11. Hoffmann U, Fischereder M, Kruger, B, et al.: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15:407-410.
12. Merten G, Burgess WP, Gray LV, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291:2328-2334.
13. Briguori C, Airoldi F, D'Andrea D, et al.: Renal insufficiency following contrast media administration trial (REMEDIAL). A randomized comparison of 3 preventive strategies. Circulation 2007, 115: 1211-1217.
14. Recio-Mayoral A, Chaparro M, Prado B, et al.: The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol 2007, 49:1283-1288.
15. Brar S, Jorgensen MB, Kotlewski A, et al.: A randomized controlled trial for the prevention of contrast induced nephropathy with sodium bicarbonate vs. sodium chloride in persons undergoing coronary angiography (MEENA Trial). Paper presented at the 56th Annual Scientific Session of the American College of Cardiology. New Orleans, LA; March 24-27, 2007. Abstract 2409.
16. Solomon R, Natarajan MK, Doucet S, et al.: The CARE (Cardiac Angiography in REnally Impaired Patients) Study: a randomized, double-blind trial of contrast-induced nephropathy in high risk patients. Circulation 2007, 115:3189-3196.
17. Davidson C, Stacul F, McCullough PA, et al.: Contrast medium use. Am J Cardiol 2006, 98(suppl):42K-58K.
18. Barrett B, Carlisle EJ: Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993, 188:171-178.
19. Aspelin P, Aubry P, Fransson S, et al.: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003, 348:491-499.
20. Hardiek K, Katholi RE, Robbs RS, Katholi CE: Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications 2007, in press.
21. Barrett B, Katzberg R, Thomsen HS: Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006, 41:815-821.
22. Deray G: Dialysis and iodinated contrast media. Kidney Int 2006, 69:S25-S29.
23. Thomsen HS: Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004, 14:1654-1656.
24. Marckmann P, Skov L, Rossen K, et al.: Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17:2359-2362.
25. Marenzi G, Lauri G, Campodonico J, et al.: Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006, 119:155-162.